Alpha-galactosylceramide

DB12232InvestigationalSmall molecule

KRN7000 has been used in trials studying the treatment of Lung Cancer, Chronic Hepatitis C, Hepatitis B, Chronic, Unspecified Adult Solid Tumor, Protocol Specific, and Prevention of GvHD in Patients...

Mechanism: Pharmacologically active on Antigen-presenting glycoprotein CD1d
Curator reviewed
Formula / weight: C₅₀H₉₉NO₉ · 858.3224 g/mol (avg)
Also known as: 1-O-(α-D-galactopyranosyl)-N-hexacosanoylphytosphingosine
Code names: AGL-582 · KRN-7000 · RGI-2001

Resolves to

Compound

UNIIWX671898JFCAS158021-47-7ChEMBLCHEMBL384200ChEBI466659PubChem2826713

Structure

InChIKeyVQFKFAKEUMHBLV-BYSUZVQFSA-NSMILESCCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC

Targets

P15813CD1D

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

9Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Alpha-galactosylceramide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account